Curate (Associate & Priest-in-Charge) Traverse City, MI Ya no son extranjeros: Un diálogo acerca de inmigración Una conversación de Zoom June 22 @ 7 p.m. ET Rector Shreveport, LA AddThis Sharing ButtonsShare to PrintFriendlyPrintFriendlyShare to FacebookFacebookShare to TwitterTwitterShare to EmailEmailShare to MoreAddThis Course Director Jerusalem, Israel Canon for Family Ministry Jackson, MS Rector Hopkinsville, KY Episcopal Migration Ministries’ Virtual Prayer Vigil for World Refugee Day Facebook Live Prayer Vigil June 20 @ 7 p.m. ET Virtual Celebration of the Jerusalem Princess Basma Center Zoom Conversation June 19 @ 12 p.m. ET Press Release Service Assistant/Associate Priest Scottsdale, AZ Submit a Job Listing Remember Holy Land Christians on Jerusalem Sunday, June 20 American Friends of the Episcopal Diocese of Jerusalem Inaugural Diocesan Feast Day Celebrating Juneteenth San Francisco, CA (and livestream) June 19 @ 2 p.m. PT Rector Martinsville, VA Posted Dec 1, 2017 Rector/Priest in Charge (PT) Lisbon, ME New Berrigan Book With Episcopal Roots Cascade Books The Church Investment Group Commends the Taskforce on the Theology of Money on its report, The Theology of Money and Investing as Doing Theology Church Investment Group Episcopal Charities of the Diocese of New York Hires Reverend Kevin W. VanHook, II as Executive Director Episcopal Charities of the Diocese of New York Bishop Diocesan Springfield, IL An Evening with Presiding Bishop Curry and Iconographer Kelly Latimore Episcopal Migration Ministries via Zoom June 23 @ 6 p.m. ET Assistant/Associate Rector Washington, DC Rector and Chaplain Eugene, OR Priest Associate or Director of Adult Ministries Greenville, SC Rector Knoxville, TN Join the Episcopal Diocese of Texas in Celebrating the Pauli Murray Feast Online Worship Service June 27 This Summer’s Anti-Racism Training Online Course (Diocese of New Jersey) June 18-July 16 Director of Music Morristown, NJ Assistant/Associate Rector Morristown, NJ Submit a Press Release The Church Pension Fund Invests $20 Million in Impact Investment Fund Designed to Preserve Workforce Housing Communities Nationwide Church Pension Group Featured Events Associate Rector Columbus, GA Associate Priest for Pastoral Care New York, NY Cathedral Dean Boise, ID Pour écouter l’émission cliquer sur : http://frequenceprotestante.com/emission/magazine-anglican116 500 américains ont été tués lors de la Première Guerre Mondiale. À la Cathédrale américaine de Paris, avenue George V, a été inauguré dès 1923, un mur mémorial sur lequel sont apposées des plaques commémoratives.Ces plaques portent les insignes des différentes unités militaires qui ont servi en Europe de 1917 à 1918 avec les pertes pour chaque unité. Mais on peut aussi y voir des plaques aux noms d’unités civiles volontaires dont certaines sont venues en aide à la France dès 1914.C’est l’histoire de ces unités que relate dans le Magazine Anglican, Ellen Hampton, historienne et écrivaine, membre de la Cathédrale.À l’appel des gouverneurs de l’hôpital américain de Paris (situé à Neuilly), un corps d’étudiants américains de l’École des Beaux-Arts a transformé un lycée en hôpital. À l’issue de cette transformation, réalisée en trois semaines, l’hôpital pouvait, dès septembre 1914, offrir 175 lits aux blessés de la bataille de la Marne.En janvier 1915 est arrivée la première équipe médicale des États-Unis, en provenance de l’hôpital de Cleveland. Suivront d’autres équipes et d’éminents praticiens dont George Crile, Harvey Cushing et Mary Merritt Crawford, l’une des premières femmes chirurgiens de l’hôpital de Brooklyn.Mais Neuilly était bien loin du front et ce fut le début de la grande aventure des ambulanciers américains sur le front. Avec quelques centaines de voitures, on estime qu’ils ont transporté plus de 400 000 blessés.Les ambulanciers transportaient les blessés du front à un hôpital de campagne ou à un train sanitaire. Un travail très dangereux, au cours duquel au moins 155 ont perdu la vie sur les routes boueuses de l’Est de la France.Nombre de ces ambulanciers s’engageront dans l’Escadrille Lafayette, un corps de pilotes volontaires qui ont appris à voler dans le Sud de la France. 67 d’entre eux, tués au combat, sont enterrés à Marnes-la-Coquette près de Paris.Le nom de l’escadrille avait été choisi en hommage à Lafayette et à l’aide apportée par la France aux insurgés de la guerre d’indépendance américaine.Au moment de l’arrivée du corps expéditionnaire américain en 1917, le général Pershing s’est rendu au cimetière de Picpus sur la tombe de Lafayette. L’histoire lui prête cette phrase historique : Lafayette, nous voici !Pour écouter l’émission et les enregistrements d’époque des chansons populaires, choisies par Mark Caroll, paroissien de la Cathédrale américaine, cliquer sur : http://frequenceprotestante.com/emission/magazine-anglicanLe Magazine Anglican est diffusé, le 4e samedi du mois, à l’antenne parisienne de Fréquence Protestante. Via la radio numérique, chaque émission est accessible pendant six mois, aux auditeurs francophones d’Europe, d’Amérique, d’Afrique et d’Océanie.Animé depuis 2012, par Laurence Moachon, paroissienne de la Cathédrale de la Sainte Trinité à Paris, le Magazine Anglican a pour objectif de mieux faire connaître la tradition anglicane / épiscopale Rector (FT or PT) Indian River, MI Missioner for Disaster Resilience Sacramento, CA Rector Bath, NC Curate Diocese of Nebraska TryTank Experimental Lab and York St. John University of England Launch Survey to Study the Impact of Covid-19 on the Episcopal Church TryTank Experimental Lab Featured Jobs & Calls Associate Rector for Family Ministries Anchorage, AK Rector Albany, NY Le Magazine Anglican : Lafayette nous voici ! Émission de novembre 2017 Submit an Event Listing Family Ministry Coordinator Baton Rouge, LA Rector Belleville, IL In-person Retreat: Thanksgiving Trinity Retreat Center (West Cornwall, CT) Nov. 24-28 Youth Minister Lorton, VA Priest-in-Charge Lebanon, OH Seminary of the Southwest announces appointment of two new full time faculty members Seminary of the Southwest Rector Smithfield, NC Rector Washington, DC Rector Pittsburgh, PA Rector Collierville, TN Director of Administration & Finance Atlanta, GA Rector Tampa, FL
Ex-Charity Commission board member Claire Dove appointed as VCSE sector Crown Representative Claire Dove has been named as the new Crown Representative of the Voluntary, Community and Social Enterprise sector (VCSE).Dove succeeds Michael O’Toole, and will work alongside government departments and the Crown Commercial Service on strengthening the sector, supporting the upcoming Civil Society Strategy, and encouraging VSCE organisations to operate more commercially.Claire Dove VCSE Crown Representative, said:“It’s an honour to take on this role. Millions of people benefit from the work that charities and social enterprises do and I cannot wait to get started to ensure this sector continues to go from strength to strength.”Tracey Crouch, Minister for Sport and Civil Society, said: Advertisement Melanie May | 28 February 2018 | News “Claire will bring a lot of passion and experience into this role – having chaired Social Enterprise UK among other organisations. I am looking forward to working alongside her and the Crown Commercial Service to help support the VCSE sector and societies across the country.”Dove has led the Blackburne House Group, which provides adult and community education, since its inception. From December 2007 to January 2017 she was Chair of Social Enterprise UK (SEUK). She is also a member of the Alder Hey Hospital Trust and, until recently, was a Board Member for the Charity Commission. She has chaired the Liverpool Fairness Commission on behalf of Liverpool City Council, is currently serving on the Liverpool Mayoral Development Board and is chair of the Society Advisory Board for the British Council.Dove was awarded an MBE for her work in the mid-nineties. She received an OBE in 2013 and was given the Queens Lifetime Achievement Award for Enterprise Promotion.Image: Claire Dove OBE, Social Enterprise UK, 2016 Tagged with: Charity Commission Recruitment / people 182 total views, 2 views today AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis5 181 total views, 1 views today AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis5 About Melanie May Melanie May is a journalist and copywriter specialising in writing both for and about the charity and marketing services sectors since 2001. She can be reached via www.thepurplepim.com.
Previous articleHAT Market Analysis for 5/3/21 with John Zanker of Risk Management CommoditiesNext articleAg Economy Barometer Remains Strong; Producers Concerned About Possible Changes in Estate Tax Policy Eric Pfeiffer SHARE SHARE By Eric Pfeiffer – May 3, 2021 Facebook Twitter Audio Playerhttps://hoosieragtoday.com/wp-content/uploads/2021/05/pioneer-050321-wrap.mp300:0000:0000:00Use Up/Down Arrow keys to increase or decrease volume.Pioneer agronomist Dan Emmert says planters were rolling in southwest Indiana that first week of April and now they’re about 80% done with corn and soybean planting in that region. With conditions being dry and cool, he does have some concerns.“Emergence looks good for the most part, but we were cool, so things took some time to come up. With that, we’re seeing a greater opportunity for insect feeding as that stuff was laying in the ground longer. So, we’re seeing some pockets of a wireworm and seed corn maggot feeding.”Emmert says the bigger concern stems from the 3 inches of rain received in some areas last week. For that corn that was planted a month ago, “The seed treatment protection is starting to wear off, and so one of the things I’m kind of worried about, or going to be keeping an eye on here over the next week for the early planted stuff, is seedling blight. Especially in those poorly drained areas with high residue.“And for the seeds that were planted late last week just ahead of the rain, I’m really going to keep an eye on how long those soils have been saturated. Especially with more rain coming in early this week, if we’ve got pockets of the field that have been saturated for more than 48 hours, we really start to worry about the survival of those seedlings and keep an eye on those patches for replant,” says Emmert.With more rain in the forecast, Emmert is urging farmers to practice patience before getting back out with the planter. He says there are still a couple of weeks left before we give up too much yield potential, so there’s no need to be mudding things in to get that last 20% completed. Facebook Twitter Home Indiana Agriculture News Pioneer Agronomist: 80% Done With Planting in Southwest Indiana Pioneer Agronomist: 80% Done With Planting in Southwest Indiana
GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs Twitter WhatsApp Previous articleValanciunas records double-double; Grizzlies beat KingsNext articleWallace becomes 1st Black driver to lead lap at Daytona 500 Digital AIM Web Support Twitter Local NewsBusiness WhatsApp PARIS–(BUSINESS WIRE)–Feb 15, 2021– Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the journal BioDrugs has published results from REVEAL, the Phase I/IIa clinical trial that evaluated the safety of LUMEVOQ ® gene therapy in subjects with ND4 Leber Hereditary Optic Neuropathy (LHON) and determined the dose subsequently used in the Phase III trials RESCUE and REVERSE. The paper*, published in the February issue of BioDrugs under the title “Safety of intravitreal gene therapy for treatment of subjects with Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial ND4 gene – The REVEAL study”, discusses the results that were the first to demonstrate the favorable safety profile of LUMEVOQ ® while also providing signals of efficacy that were more fully investigated in the Phase III trials. “The REVEAL study demonstrated that treatment with lenadogene nolparvovec (rAAV2/2-ND4, or LUMEVOQ ® ) is well-tolerated over both the short and long term by LHON patients with the ND4 mutation,” commented lead investigator Dr. Catherine Vignal, MD, Department of Neuro Ophthalmology and Emergencies, Rothschild Foundation Hospital, Paris, France, and Centre Hospitalier National d’Ophtalmologie des Quinze Vingts, Paris, France . “As the gene therapy’s first clinical study, it gave encouraging results and paved the way for the efficacy investigations of the Phase III trials RESCUE and REVERSE.” “ This study confirms the gene therapy’s favorable long-term safety and further demonstrates that the trends that were initially observed have been maintained for at least five years,” said Dr.José-Alain Sahel, MD, co-founder of GenSight and founder of the Institut de la Vision (Sorbonne-Université/Inserm/CNRS), Paris, France, where LUMEVOQ ® ’s underlying Mitochondrial Targeting Sequence technology was developed. Dr. Sahel is also the Director of Institut Hospitalo-Universitaire FOReSIGHT, and Distinguished Professor and Chairman of the Department of Ophthalmology at the University of Pittsburgh School of Medicine and UPMC (University of Pittsburgh Medical Center), USA. REVEAL trial data and analyses were integral components of the evidence package submitted by GenSight Biologics in September 2020 to the European Medicines Agency when it filed a Marketing Authorisation Application (MAA) for LUMEVOQ ® as treatment for patients with visual loss due to LHON caused by a confirmed mutation in the ND4 mitochondrial gene. The agency’s decision is expected in Q4 2021. GenSight Biologics expects to report topline results from its third Phase III trial REFLECT in Q2 2021. The trial will evaluate the efficacy and safety of bilateral injections of LUMEVOQ ® in subjects with LHON caused by a mutated ND4 gene. REFLECT was designed under a Special Protocol Assessment agreement with the US Food and Drug Administration (FDA). REVEAL Trial Design and Key Results REVEAL was an open-label, single-center, dose escalation study launched in 2014 that evaluated the safety and tolerability of lenadogene nolparvovec in 15 subjects with ND4 LHON, who were followed for up to 5 years following a single intravitreal injection to their worst affected eye. No limits were placed on the time since onset of vision loss. Subjects were enrolled sequentially in 4 cohorts of 3 subjects each, with each cohort receiving increasing doses of the gene therapy a. Dose escalation proceeded only after a safety evaluation by an independent data safety monitoring board (DSMB). A final extension cohort received the dose that the DSMB determined to have the best benefit-risk ratio among those administered to the four previous cohorts. LUMEVOQ ® treatment was well-tolerated over the 5-year follow-up period. No Serious Adverse Events were considered related to treatment; no unexpected adverse events occurred; and no Grade 3 or 4 Common Terminology Criteria for Adverse Events (CTCE) were reported. Anterior chamber inflammation and vitritis were mostly managed with topical steroids. This safety profile has been subsequently affirmed in the Phase III trials RESCUE and REVERSE. b The occurrence of ocular inflammation was used by the DSMB to recommend 9×10 10 viral genomes [vg]/eye as the optimal dose to carry forward into the Phase III investigation. Despite treatment after considerable time since onset (4.6 years on average after vision loss), the six subjects who received this dose achieved a mean visual acuity improvement over baseline of -0.68 LogMAR for treated eyes, and -0.64 LogMAR for untreated eyes, with a mean (±SD) final value of +1.77 (±0.52) LogMAR and +1.78 (±0.34) LogMAR, respectively. While meaningful, this improvement is less impressive than that observed in the Phase III trials RESCUE and REVERSE, as the subjects in the later trials were treated earlier in the course of their disease. The paper is available on https://rdcu.be/ce7s4. *About the paper: Safety of intravitreal gene therapy for treatment of subjects with Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial ND4 gene – The REVEAL study Authors: Catherine Vignal-Clermont 1,2, Jean-François Girmens 2,3, Isabelle Audo 2,3,4, Saddek Mohand Said 2,3,4, Marie-Hélène Errera 2,3,7, Lise Plaine 2,3, Denis O’Shaughnessy 5, Magali Taiel 5, José-Alain Sahel 3,4,6,7 Affiliations: 1 Department of Neuro Ophthalmology and Emergencies, Rothschild Foundation Hospital, Paris, France 2 Centre Hospitalier National d’Ophtalmologie des Quinze Vingts, Paris, France 3 CHNO des Quinze-Vingts, Institut Hospitalo-Universitaire FOReSIGHT, INSERM-DGOS CIC 1423, Paris, France 4 Sorbonne Université, INSERM, CNRS, Institut de la Vision, 75012 Paris, France 5 GenSight Biologics, Paris, France 6 Fondation Ophtalmologique A. de Rothschild, 25-29 rue Manin, 75019 Paris 7 Department of Ophthalmology, The University of Pittsburgh School of Medicine, Pittsburgh, USA Notes: a The four dosages investigated were 9×10 9 vg/eye [Cohort 1], 3×10 10 vg/eye [Cohort 2], 9×10 10 vg/eye [Cohort 3] and 1.8×10 11 vg/eye [Cohort 4]. b See Newman NJ, Yu-Wai-Man P, Carelli V, et al. Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset. Ophthalmology 2021; In Press, 12 Januuary 2021, and Yu-Wai-Man P, Newman NJ, Carelli V, et al. Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. Sci. Transl. Med. 2020; 12: eaaz7423. 9 December 2020. About GenSight Biologics GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, LUMEVOQ ® (GS010; lenadogene nolparvovec), has been submitted for marketing approval in Europe for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. About Leber Hereditary Optic Neuropathy (LHON) Leber Hereditary Optic Neuropathy (LHON) is a rare maternally inherited mitochondrial genetic disease, characterized by the degeneration of retinal ganglion cells that results in brutal and irreversible vision loss that can lead to legal blindness, and mainly affects adolescents and young adults. LHON is associated with painless, sudden loss of central vision in the 1 st eye, with the 2 nd eye sequentially impaired. It is a symmetric disease with poor functional visual recovery. 97% of patients have bilateral involvement at less than one year of onset of vision loss, and in 25% of cases, vision loss occurs in both eyes simultaneously. The estimated incidence of LHON is approximately 800-1,200 new patients who lose their sight every year in the United States and the European Union. About LUMEVOQ ® (GS010; lenadogene nolparvovec) LUMEVOQ ® (GS010; lenadogene nolparvovec) targets Leber Hereditary Optic Neuropathy (LHON) by leveraging a mitochondrial targeting sequence (MTS) proprietary technology platform, arising from research conducted at the Institut de la Vision in Paris, which, when associated with the gene of interest, allows the platform to specifically address defects inside the mitochondria using an AAV vector (Adeno-Associated Virus). The gene of interest is transferred into the cell to be expressed and produces the functional protein, which will then be shuttled to the mitochondria through specific nucleotidic sequences in order to restore the missing or deficient mitochondrial function. “LUMEVOQ” was accepted as the invented name for GS010 (lenadogene nolparvovec) by the European Medicines Agency (EMA) in October 2018. About RESCUE and REVERSE RESCUE and REVERSE are two separate randomized, double-masked, sham-controlled Phase III trials designed to evaluate the efficacy of a single intravitreal injection of GS010 (rAAV2/2- ND4 ) in subjects affected by LHON due to the G11778A mutation in the mitochondrial ND4 gene. The primary endpoint measured the difference in efficacy of GS010 in treated eyes compared to sham-treated eyes based on Best-Corrected Visual Acuity (BCVA), as measured with the ETDRS at 48 weeks post-injection. The patients’ LogMAR (Logarithm of the Minimal Angle of Resolution) scores, which are derived from the number of letters patients read on the ETDRS chart, was used for statistical purposes. Both trials were adequately powered to evaluate a clinically relevant difference of at least 15 ETDRS letters between treated and untreated eyes adjusted to baseline. The secondary endpoints involved the application of the primary analysis to best-seeing eyes that received GS010 compared to those receiving sham, and to worse-seeing eyes that received GS010 compared to those that received sham. Additionally, a categorical evaluation with a responder analysis was evaluated, including the proportion of patients who maintain vision (< ETDRS 15L loss), the proportion of patients who gain 15 ETDRS letters from baseline and the proportion of patients with Snellen acuity of >20/200. Complementary vision metrics included automated visual fields, optical coherence tomography, and color and contrast sensitivity, in addition to quality of life scales, bio-dissemination and the time course of immune response. Readouts for these endpoints were at 48, 72 and 96 weeks after injection. The trials were conducted in parallel, in 37 subjects for REVERSE and 39 subjects for RESCUE, in 7 centers across the United States, the UK, France, Germany and Italy. Week 96 results were reported in 2019 for both trials, after which patients were invited to a long-term follow-up study that will last for three years. ClinicalTrials.gov Identifiers: REVERSE: NCT02652780 RESCUE: NCT02652767 View source version on businesswire.com:https://www.businesswire.com/news/home/20210214005044/en/ CONTACT: GenSight Biologics Chief Financial Officer Thomas Gidoin [email protected] +33 (0)1 76 21 72 20LifeSci Advisors Investor Relations Guillaume van Renterghem [email protected] +41 (0)76 735 01 31RooneyPartners Media Relations Marion Janic [email protected] +1 646-537-5649Orpheon Finance Retail Investors James Palmer [email protected] +33 (0)7 60 92 77 74 KEYWORD: FRANCE EUROPE INDUSTRY KEYWORD: HEALTH GENETICS CLINICAL TRIALS PHARMACEUTICAL OPTICAL BIOTECHNOLOGY SOURCE: GenSight Biologics Copyright Business Wire 2021. PUB: 02/15/2021 01:30 AM/DISC: 02/15/2021 01:30 AM http://www.businesswire.com/news/home/20210214005044/en By Digital AIM Web Support – February 15, 2021 Facebook Pinterest Pinterest TAGS Facebook
Pinterest Facebook By News Highland – March 28, 2018 Pinterest Important message for people attending LUH’s INR clinic Google+ News, Sport and Obituaries on Monday May 24th Facebook All four defendants acquitted in Belfast rape trial Previous articleHarps v Derry moved to 5pm Easter MondayNext articleGovernment must prioritise disability services – Pringle News Highland Twitter Google+ Nine til Noon Show – Listen back to Monday’s Programme WhatsApp Loganair’s new Derry – Liverpool air service takes off from CODA All 4 defendants have been acquitted in the Belfast Rape Trial.Paddy Jackson and Stuart Olding have been found not guilty of rape, while Mr. Jackson has also been found not guilty of sexual assault.The Ireland and Ulster rugby players had denied raping a 19-year-old student at a party in Jackson’s south Belfast home in June 2016.Blane McIlroy has been found not guilty of exposure while Rory Harrison has been found not guilty of perverting the course of justice and withholding information.The trial in front of a jury of 8 men and 3 women lasted 9 weeks. Homepage BannerNews DL Debate – 24/05/21 Arranmore progress and potential flagged as population grows WhatsApp RELATED ARTICLESMORE FROM AUTHOR Twitter
Twitter RELATED ARTICLESMORE FROM AUTHOR Important message for people attending LUH’s INR clinic Pinterest Pinterest WhatsApp Arranmore progress and potential flagged as population grows Nine til Noon Show – Listen back to Monday’s Programme Google+ Facebook Homepage BannerNews Woman injured in fatal Bundoran crash transferred to Dublin hospital Loganair’s new Derry – Liverpool air service takes off from CODA Facebook Previous articleBallygawley bus bombing memorial unveiled on 30th anniversaryNext articleDonegal homeowners insure content for less according to AA News Highland By News Highland – August 19, 2018 A man in his 20s arrested by Gardaí investigating a fatal traffic collision in Bundoran in the early hours of Sunday morning has been released without charge, a file will be prepared for the Director of Public Prosecutions.Two men in their 20s seriously injured in the collision are continuing to receive treatment at Sligo University Hospital, while the woman in her 20s critically injured is this currently being transferred to Beaumont Hospital.The local Coroner has been notified and post-mortems will be carried out on the two deceased at the mortuary in Sligo University Hospital tomorrow.An incident room has been established at Ballyshannon Garda Station and investigating Gardaí are liaising with the PSNI as part of their enquiries. The road at the crash site has been reopened to traffic.Gardaí are continuing to appeal for witnesses to come forward. Anyone with information is asked to contact Ballyshannon Garda Station on 071-9858530, the Garda Confidential Line 1800 666 111 or any Garda Station. WhatsApp News, Sport and Obituaries on Monday May 24th Google+ Twitter Community Enhancement Programme open for applications
Previous Article Next Article What does e give you?On 1 Mar 2000 in Personnel Today Comments are closed. Thehype around e-learning might lead you to believe it is a cure for the world’sills. What difference is it really making to organisations? Sue Clark askspeople at the forefront of the intranet revolutionNickHolleyDirector of training and development, Prudential Portfolio ManagersWehave 3,000 employees worldwide and it is impossible for us to get the righttraining to the right person at the right time using conventional methods.Usinge-learning allows us to provide development with more value and more focus. Weuse the analogy of the restaurant. Instead of giving our employees a menu ofcourses we think are good for them and when it is convenient for us, we stockthe larder and allow them to take what they require when they need it.Thereare 760 on-line courses and 90 knowledge sharing networks, which people can reachon our intranet or the Internet. They are divided into 90 learning areas under11 faculties; together we call this “The I”.E-learningcan preclude the shared experience, but The I is a part of a larger focus onperformance support which includes traditional courses (details of 3,200 arelisted on The I) and coaching. We follow up these conventional methods withshort bites of e-mail development to reinforce the learning.Wewent live in March 1999 and the 500 of our 3,000 employees who can access the intranet(the rest use the Internet) have visited the site 4,124 times, and looked at113,356 pages. While not a core driver, the success of e-learning contributedto our coming in 30 per cent under budget last year.RichardMcGreevyHead of learning distribution ,CGU InsuranceOurnetworked training PCs were set up primarily to enable access of technicaltraining to our branch-based staff at a time of great activity – the mergerbetween Commercial Union and General Accident. Thekey drivers, therefore, were instant and flexible availability of a wide rangeof modules coupled with the advantages of local delivery of training whichreduced time wasted on travel and minimised absence from the workplace.Staffwho were used to classroom events had to adapt to greater use of technologycoupled with self management of their learning programmes. While the long termcost of this delivery medium is less than traditional means, many staff stillhanker for the residential course at the staff college.Ourexperience shows that delivery to the desktop is most effective for technicaltraining of short duration. Our staff prefer to engage in prolonged learningevents on separate PCs set in quieter sections of the office. For the future wesee mixed delivery solutions with e-learning focusing on just-in-time training.SueTolleySenior manager, e-learning, Lloyds TSBLloydsTSB launched its corporate university last year and with it the launch ofe-learning. We want to provide just-in-time learning at the desk, through ourweb site, accessed through both the Internet and our intranet.Recentdevelopments have included an e-learning familiarisation programme fortrainers. This was conducted on-line and trainers learned how to coachdelegates and facilitate discussion groups using this medium.Itis encouraging that we have more requests from trainers to develop skills inon-line course design and that many see e-learning as an opportunity, not athreat.Twoof our residential training sites have cyber-cafés, used by delegates andtrainers. These facilities supplement residential programmes and provide theopportunity to experiment and become familiar with e-learning.Weare about to launch the first phase of our web-enabled career development toolsto an audience of 20,000. This was developed in-house in a short time scale.The web technology provided us with cost effective methods to distribute andkeep material up to date.Opportunitiesfor the future include the development of on-line training transactions,testing, and the sharing of knowledge/information that will enable us toimprove our efficiency.Inusing web technology, we have embarked upon a journey, although with the webenvironment changing at such a pace who knows where this will lead? This ispart of the challenge for the function.NeilRodenHR director, Royal Bank of ScotlandThesheer pace of change in the financial and retail banking sectors is immense,and to meet these demands, we realised our whole approach to training also had tochange dramatically. This paradigm shift means that we require a learningplatform that is more flexible, more consistent and accommodates the differinglearning styles of our staff.Web-basedlearning delivers these, particularly self-paced learning, and is a welcomeaddition to our learning platform.Ouron-line learning programme is part of an HR web delivery programme to deliverself-service HR to 20,000 staff through our HR intranet site. A key part ofthis programme has been a significant investment in a bespoke learning networkstretching into 650 branches. This network has allowed the bank to delivertraining via the intranet to approximately 7,000 employees.Inaddition it has streamlined the administration process with functionality suchas on-line course booking and ordering of distance learning. This has alreadydelivered a return on capital of over 700 per cent.Anotherkey element in the bank’s on-line learning strategy enables staff to accessbroadcast events without leaving their branch. The broadcasts, sent viasatellite, are viewed using PCs within each branch.AngelaGoldbergSenior HR manager, London Borough of NewhamOnlinelearning enables staff to address their development needs quickly andaccurately. Contrast this to a longish wait for an appropriate course which, byits nature, cannot possibly be individually tailored. Time and money spent ontraining is thus used more effectively in many cases. People enjoy the privacyof the approach, and welcome the freedom to repeat things until they reallyunderstand. It also avoids things like role play which can inhibitparticipation and learning for some.Alternatively,some have found it a lonely experience and miss group interaction which, inturn, detracts from their learning. Obviously, one key message is thatindividuals can legitimately choose the method to suit their particularlearning style.However,it is also important to encourage experimentation with new things. Related posts:No related photos.
FacebookTwitterLinkedInEmailFARMINGTON, Utah-Wednesday morning, the Big Sky Conference announced its football schedule for the upcoming spring.This includes Utah-based schools Southern Utah University and Weber State University.The season will run from February 27-April 10.The Thunderbirds and Wildcats’ seasons are as follows:Southern UtahFebruary 27 @ Cal PolyMarch 6 @ Northern ColoradoMarch 13 Idaho State (the Thunderbirds’ home opener)March 27 Weber StateApril 3 @ Northern ArizonaApril 10 Idaho (Senior Day for the Thunderbirds)Weber StateFebruary 27 @ Idaho StateMarch 6 Montana State (the Wildcats’ home opener)March 13 Northern ArizonaMarch 27 @ Southern UtahApril 3 Northern Colorado (Senior Day for the Wildcats)April 10 @ UC Davis Brad James Written by Tags: Big Sky Conference November 4, 2020 /Sports News – Local Big Sky Conference Football Schedule Released
Both the companies will collaborate and develop the market for LNG supply by road from LNG Terminal in Hazira (District Surat), Gujarat INOX India and SHELL Energy India sign MOU for delivery of LNG through road transport. (Credit: INOX India) INOX India has signed a memorandum of understanding (MoU) with Royal Dutch Shell’s subsidiary, Shell Energy India (SEI) for LNG distribution in India.Both the companies will collaborate and develop the market for LNG supply by road from LNG Terminal in Hazira (District Surat), Gujarat of Shell.The MoU seeks to create an LNG distribution infrastructure that includes logistics and receiving facilities and will also provide LNG access to customers who are not connected to pipelines.The infrastructure is expected to increase the penetration and consumption of LNG to commercial and industrial (C&I) users across the country.INOX India executive director Siddharth Jain said: “Our partnership with Shell, underlines INOX’s innovativeness and our futuristic approach.“LNG is not only a clean and cost-effective fuel but is also safe and reliable. We are delighted that our collaborated efforts will make this green fuel more accessible.“A larger gas-based industrial ecosystem augurs well with Indian economy as well as for the environment at the same time and is a win-win situation for all stakeholders.”INOX India has installed more than 35 LNG facilities in IndiaThe agreement also includes the development of market for LNG as a transport fuel for long-haul heavy-duty trucks and buses.SEI currently owns and operates a 5 million tonnes per annum (MMTPA) LNG receiving, storage and regasification terminal at Hazira in Gujarat and is also constructing a truck loading facility at its Hazira Terminal.INOX has installed over small scale 35 LNG facilities in India under its GoLNG brand, following the commissioning of first such installation at the Halol Plant of General Motors in year 2010.The company’s GoLNG transport tankers have collectively logged over 6.5 million km and distributed approximately 100,000 metric tonnes of LNG to its consumers in the country.In January last year, Shell Gas has taken full ownership in the $425.4m Hazira LNG and Port in India by buying out the remaining 26% stake from Total Gaz Electricité Holdings France.
Back to overview,Home naval-today Zheng He Passes Through the Panama Canal View post tag: Panama Training & Education Share this article View post tag: Navy The “Zheng He” oceangoing training ship of the Navy of the Chinese People’s Liberation Army (PLA) which was deployed on the “Harmonious Mission – the ‘Zheng He’ oceangoing training ship’s voyage around the world” passed through the Panama Canal successfully at 02:00 of July 9, 2012, local time, PLA Daily informed.With this passage, the ship made the second successful passage through man-made canals, the first one being the Suez Canal, through which the ship passed on May 27, 2012.The “Zheng He” is headed for the South Pacific Ocean, nevertheless before it casts off for its next stop within its world- wide journey, the ship will make a call at the Gulf of Panama for refueling and replenishment.According to Song Hui, head of the teaching group on the ship and deputy director of the Training Department of the Dalian Naval Academy of the PLA Navy, the passage served as an opportunity for training, in the course of which the midshipmen acted as probationary navigation officers and watch officers in batches and participated in various work activities such as translation, guidance and mooring.[mappress]Naval Today Staff, July 10, 2012 View post tag: Canal View post tag: He July 10, 2012 View post tag: passes View post tag: News by topic View post tag: Zheng View post tag: Naval Zheng He Passes Through the Panama Canal